Press Releases

Poxel Announces Patient Enrollment Completed for Imeglimin Phase 2b Clinical Trial in Type 2 Diabetes in Japan

Jun 30, 2016

Poxel Announces Positive Results From the First Stage of the Ongoing PXL770 Phase 1 Trial

Jun 20, 2016

Poxel Makes Available to the Public Its 2015 Reference Document

Jun 14, 2016

Poxel Presents New Data on Imeglimin’s Dual Mechanism of Action at the American Diabetes Association’s 76th Scientific Sessions

Jun 13, 2016

Poxel to Present Imeglimin Data at the American Diabetes Association’s 76th Scientific Sessions

May 17, 2016

Poxel Provides 1Q16 Cash Figures

May 5, 2016

Poxel Plans to Conduct Registered Initial Public Offering in the United States

May 4, 2016

Poxel Announces Election of Pierre Legault as Chairman of the Board of Directors

Apr 18, 2016

Poxel Reports Results for Fiscal Year 2015 and Provides Corporate Update

Apr 1, 2016

Poxel has been Granted U.S. Composition of Matter Patent for Direct AMPK Activator PXL770 for the Potential Treatment of Type 2 Diabetes and Related Disorders

Mar 29, 2016